Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/27/2005US20050239900 Use of low molecular weight amino alcohols in ophthalmic compositions
10/27/2005US20050239899 Beta-secretase inhibitors
10/27/2005US20050239898 Compounds for use in the treatment of aids and other viral diseases and HIV-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
10/27/2005US20050239896 A 5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid, acid ester, sulfonic acid or amide derivatives, for treating Alzheimer's disease, Parkinson's disease and Huntington's disease, epilepsy, stroke, depression, glaucoma
10/27/2005US20050239895 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
10/27/2005US20050239894 Topical composition
10/27/2005US20050239893 2-[4-((((3,5-dimethylphenyl)amino)carbonyl)methyl)phenoxy]-2-methyl propionic acid (efaproxiral); free of polymeric impurities; prepared by coupling substituted aniline with 4-hydroxyphenylacetic acid to yield substituted phenol, adding product to alkyl ester halide to yield ethyl ester, saponifying
10/27/2005US20050239892 Therapeutic avenathramide compounds
10/27/2005US20050239891 Use of citrulline within the framework of intestinal insufficiency
10/27/2005US20050239890 Methods for decreasing detrusor muscle overactivity
10/27/2005US20050239889 In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
10/27/2005US20050239888 Pharmaceutical compositions containing keto-acids for endoperitoneal administration
10/27/2005US20050239887 Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
10/27/2005US20050239886 Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes
10/27/2005US20050239885 Processes for the preparation of simvastatin
10/27/2005US20050239884 Compositions comprising hmg-coa reductase inhibitor
10/27/2005US20050239883 Composition for lowering internal lipid content
10/27/2005US20050239882 Pharmaceutical compositions useful in prevention and treatment of beta-amyloid protien-induced disease
10/27/2005US20050239881 viricides; polymerase inhibitors; therapy for genetic engineered virus
10/27/2005US20050239880 Methods for treating retroviral infections
10/27/2005US20050239879 Polymorphic forms of (1-{3-[3-(4-cyano-3-methoxy-phenyl) ureido]-phenyl}-ethyl)-carbamic acid-2-cyano-1-ethyl-ethyl ester
10/27/2005US20050239878 Inhibitors of methionine aminopeptidase-2 and uses thereof
10/27/2005US20050239877 Synthetic lactone formulations and method of use
10/27/2005US20050239876 Tocopherol and tocotrienol aerosols
10/27/2005US20050239875 Derivatives of dihydronepetalactone and method for preparation
10/27/2005US20050239873 2 Methoxy antimycin a derivatives and methods of use
10/27/2005US20050239872 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma
10/27/2005US20050239871 Statins for the treatment of ocular hypertension and glaucoma
10/27/2005US20050239870 Prevention of restenosis of blood vessels after trauma, angioplasty or stenting; aminoalkylamide, piperidine-, indole-, or pyrrole-amide derivatives; anticarcinogenic agents
10/27/2005US20050239869 calcium atorvastatin (Lipitor) intermediate; from intermediate 5-(4-fluorophenyl)-2-isopropyl-1-(3-morpholin-4-yl-3-oxo-propyl)-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide; via diol esters from the 1,3,5-tricarbonyl precursors in a stereoselective ruthenium-catalyzed hydrogenation (patent indexing)
10/27/2005US20050239868 Indometacin preparation for external use
10/27/2005US20050239867 Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
10/27/2005US20050239866 Fermentation product of marine actinomyces; antiproliferative agents; anticancer agents
10/27/2005US20050239865 3-Cyano-2-amide-5,6-dihydrothieno[2,3-b]pyridine derivatives, e.g., tert-butyl 3-cyano-2-[(2-ethylbutanoyl)amino]-5,6-dihydrothieno[2,3-b]pyridine-7(4H) carboxylate; the compounds block the action of glucagon at its receptor and decrease the levels of plasma glucose to treat diabetes
10/27/2005US20050239863 Indole diterpene natural product and synthetic compound; Potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye
10/27/2005US20050239862 Amino ceramide-like compounds and therapeutic methods of use
10/27/2005US20050239860 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
10/27/2005US20050239859 Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
10/27/2005US20050239858 Pyrazole derivatives as gnrh inhibitors
10/27/2005US20050239857 Novel imidazoles
10/27/2005US20050239856 Method for prophylaxis and treatment of diabetic complications with 4{alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl}-3,5-dimethylbenzoic acid and derivatives
10/27/2005US20050239855 For therapy of cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/27/2005US20050239854 Body weight gain inhibitors
10/27/2005US20050239853 New compounds
10/27/2005US20050239852 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
10/27/2005US20050239851 Substituted benzoxazoles as estrogenic agents
10/27/2005US20050239850 Spraying microbiocides; reducing Salmonella in poultry
10/27/2005US20050239849 Substituted phenoxyacetic acids
10/27/2005US20050239846 Use of vanilloid receptor antagonists for the treatment of pain
10/27/2005US20050239845 Combination of proton pump inhibitor, buffering agent, and prokinetic agent
10/27/2005US20050239844 Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor
10/27/2005US20050239843 Diaminothiazoles
10/27/2005US20050239842 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
10/27/2005US20050239841 New compounds
10/27/2005US20050239840 Benzothiophenes, formulations containing same, and methods
10/27/2005US20050239838 Novel antihistamines; modulating sleep by a doxepin analog; circadian rhythm abnormality, jet lag, shift-work disorders, delayed sleep phase syndrome, advanced sleep phase syndrome and non-24 hour sleep-wake disorder
10/27/2005US20050239836 Substituted hydroxyethylamine aspartyl protease inhibitors
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239834 Novel 4-diphenylmethyl piperidine derivatives
10/27/2005US20050239833 Compositions and methods for modulating interaction between polypeptides
10/27/2005US20050239832 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
10/27/2005US20050239831 Bupivacaines
10/27/2005US20050239830 Methods of diminishing co-abuse potential
10/27/2005US20050239829 Novel piperidine compound
10/27/2005US20050239828 Spirocyclic amides as cannabinoid receptor modulators
10/27/2005US20050239827 N-(4-(2,2-difluoro-benzo(1,3)dioxol-5-ylcarbamoyl)-3-hydroxy-phenyl)-4,6-Bis-((3R,5S)-3,5-diamino-piperidin-1-yl)-(1,3,5)triazine-2-amine for example; Gram-positive and Gram-negative strains; retains potency against common antibiotic resistant strains
10/27/2005US20050239826 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
10/27/2005US20050239825 Modulation of inflammatory and metastatic processes
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239821 Viral inhibitors
10/27/2005US20050239820 1-(4-(4-Amino-1H-pyrrolo[3,2-c]pyridin-1-yl)phenyl)-3-(2-(4-fluorophenyl)acetyl)thiourea, hydrochloride salt; anticarcinogenic agents; modulators to impact angiogenesis-dependent diseases
10/27/2005US20050239819 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
10/27/2005US20050239818 acetic acid (3RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-3-yl ester, phosphodiesterase inhibitor; antiinflammatory, bronchodilator agent; bronchitis, allergic bronchitis, asthma, COPD, psoriasis, eczema, osteoarthritis, rheumatoid arthritis
10/27/2005US20050239817 Acetic acid 6-(3,4-bis-cyclopropylmethoxy-phenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-2-yl ester; low toxicity; high bioavailability; large therapeutic breadth; side effects reduction; industrial scale; antiinflammatory agent, asthma, COPD, allergic rhinitis or Crohn's disease
10/27/2005US20050239816 Amonafide salts
10/27/2005US20050239815 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor
10/27/2005US20050239814 RSV polymerase inhibitors
10/27/2005US20050239813 Pharmaceutical compositions comprising fk506 derivatives and their use for the treatment of allergic diseases
10/27/2005US20050239812 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
10/27/2005US20050239811 Tri-substituted ureas as cytokine inhibitors
10/27/2005US20050239810 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
10/27/2005US20050239809 Methods for treating and preventing hypertension and hypertension-related disorders
10/27/2005US20050239807 allopurinol, oxypurinol, or pterin-6-aldehyde derivatives containing one or more nitrate groups, used for heart failure and stable angina
10/27/2005US20050239806 Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
10/27/2005US20050239804 Method for improved chemical synthesis of guanidinium alkaloids
10/27/2005US20050239803 Method for the preparation of 5-methylpyrazine-2-carboxylic acid-4-oxide and its salts
10/27/2005US20050239802 E.g., 6-{2-[5-Chloro-2-(2,4-difluorobenzyloxy)- phenyl]cyclopent-1-enyl}-pyridine-2-carboxylic acid, used to treat prostaglandin mediated diseases that include inflammatory, neuropathic or visceral pain
10/27/2005US20050239800 Polycyclic pyrazines as potassium ion channel modulators
10/27/2005US20050239799 1-phenyl-4-benzylpiperazines dopamine receptor subtype
10/27/2005US20050239798 Method for the treatment of premenstrual and other female sexual disorders
10/27/2005US20050239797 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity
10/27/2005US20050239796 tert-butyl4-{(3,4-dimethoxyphenethyl)[2-(1H-indol-3-yl)acetyl]amino}-1-piperidine carboxylate; somatostatin receptors modulator; anticarcinogenic agent; acromegalia, hypophyseal adenomas, endocrine gastroenteropancreatic tumors including carcinoid syndrome; reducing amination of N-substituted piperidone
10/27/2005US20050239795 Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
10/27/2005US20050239794 Such as aurora-2 kinase or c-kit kinase; anticancer agents; based on benzo(4,5)furo(3,2-d)pyrimidine, 9-thia-1,5,7-triazafluorene, or pyrimido(5,4-b)indole rings; e.g. 4-(4-pyrimid-2-ylaminosulfonyl-1,4-phenylene-aminothiocarbonyl)-piperazin-1-yl)-5H-Pyrimido(5,4-b)indole
10/27/2005US20050239793 Such as aurora-2 kinase or c-kit kinase; anticancer agents; based on benzo(4,5)furo(3,2-d)pyrimidine, 9-thia-1,5,7-triazafluorene, or pyrimido(5,4-b)indole rings; e.g. 6,7-dimethoxy-4-(4-(benzodioxol-5-ylmethylaminothiocarbonyl)-piperazin-1-yl)-5H-Pyrimido(5,4-b)indole
10/27/2005US20050239792 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d)pyrimidine in the treatment of functional bowel disorder
10/27/2005US20050239791 Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
10/27/2005US20050239790 Substituted hydroxyethylamine aspartyl protease inhibitors
10/27/2005US20050239789 2-(9-bromo-3,4,10,10a-tetrahydro-1H-pyrazino[1,2-a]indol-2-yl)-cyclobutanone; treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea
10/27/2005US20050239788 Substituted with pyrrolopiperazine; schizophrenia, psychosis, depression; inhibition of the 5-HT6 receptor
1 ... 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 4508 ... 7860